Clin Infect Dis

1. WAN EYF, Chui CSL, Ng VWS, Wang Y, et al
   mRNA (BNT162b2) COVID-19 vaccination increased risk of Bell's palsy: a nested case control and self-controlled case series study.
   Clin Infect Dis. 2022 Jun 8. pii: 6604461. doi: 10.1093.
   

   >> Share

   
   
2. BART SM, Curtiss CC, Earnest R, Lobe-Costonis R, et al
   SARS-CoV-2 Outbreak at a College with High COVID-19 Vaccination Coverage-Connecticut, August-September 2021.
   Clin Infect Dis. 2022 Jun 8. pii: 6604453. doi: 10.1093.
   

   >> Share

   
   
3. LEWIS NM, Self WH, Gaglani M, Ginde AA, et al
   Effectiveness of the Ad26.COV2.S (Johnson & Johnson) COVID-19 Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States.
   Clin Infect Dis. 2022 Jun 8. pii: 6604454. doi: 10.1093.
   

   >> Share

   
   
4. LEUNG NHL, Cheng SMS, Martin-Sanchez M, Au NYM, et al
   Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine.
   Clin Infect Dis. 2022 Jun 8. pii: 6604400. doi: 10.1093.
   

   >> Share

   
   
5. RICHTERMAN A, Behrman A, Brennan PJ, O'Donnell JA, et al
   Durability of SARS-CoV-2 mRNA Booster Vaccine Protection Against Omicron Among Health Care Workers with a Vaccine Mandate.
   Clin Infect Dis. 2022 Jun 6. pii: 6603294. doi: 10.1093.
   

   >> Share

   
   

   
   J Infect Dis

6. BRUNHAM RC
   Problems with Understanding Chlamydia trachomatis Immunology.
   J Infect Dis. 2021 Dec 17. pii: 6469012. doi: 10.1093.
   

   >> Share

   
   
7. LAPOINTE HR, Mwimanzi F, Cheung PK, Sang Y, et al
   People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses.
   J Infect Dis. 2022 Jun 7. pii: 6603521. doi: 10.1093.
   

   >> Share

   
   
8. JACOBSON JM
   Immune Responses to SARS-CoV-2 Vaccination in People With HIV: A Tale of Two Pandemics.
   J Infect Dis. 2022 Jun 7. pii: 6603522. doi: 10.1093.
   

   >> Share

   
   
9. STORCH GA
   Respiratory syncytial virus (RSV) around the globe: data to help guide wise use of vaccines and anti-virals.
   J Infect Dis. 2022 Jun 6. pii: 6603523. doi: 10.1093.
   

   >> Share

   
   

   
   J Virol

10. CHEN X, Li J, Yang L, Zhou Y, et al
    Immunoglobin G Sero-Dynamics Aided Host Specific Linear Epitope Identification and Differentiation of Infected from Vaccinated Hosts.
    J Virol. 2022 Jun 6:e0014322. doi: 10.1128/jvi.00143.
    

    >> Share

    
    

    
    MMWR Morb Mortal Wkly Rep

11. KRISS JL, Hung MC, Srivastav A, Black CL, et al
    COVID-19 Vaccination Coverage, by Race and Ethnicity - National Immunization Survey Adult COVID Module, United States, December 2020-November 2021.
    MMWR Morb Mortal Wkly Rep. 2022;71:757-763.
    

    >> Share

    
    

    
    PLoS One

12. JOSHI A, Surapaneni KM, Kaur M, Bhatt A, et al
    A cross sectional study to examine factors influencing COVID-19 vaccine acceptance, hesitancy and refusal in urban and rural settings in Tamil Nadu, India.
    PLoS One. 2022;17:e0269299.
    

    >> Share

    
    
13. PATRICK L, Bakeera-Kitaka S, Rujumba J, Malande OO, et al
    Encouraging improvement in HPV vaccination coverage among adolescent girls in Kampala, Uganda.
    PLoS One. 2022;17:e0269655.
    

    >> Share

    
    
14. HILLS SL, Soeung SC, Sarath S, Morn C, et al
    An evaluation of adverse events following an immunization campaign with the live, attenuated SA14-14-2 Japanese encephalitis vaccine in Cambodia.
    PLoS One. 2022;17:e0269480.
    

    >> Share

    
    
15. ERCHICK DJ, Gupta M, Blunt M, Bansal A, et al
    Understanding determinants of vaccine hesitancy and acceptance in India: A qualitative study of government officials and civil society stakeholders.
    PLoS One. 2022;17:e0269606.
    

    >> Share

    
    
16. KHAIRKHAH N, Bolhassani A, Agi E, Namvar A, et al
    Immunological investigation of a multiepitope peptide vaccine candidate based on main proteins of SARS-CoV-2 pathogen.
    PLoS One. 2022;17:e0268251.
    

    >> Share

    
    
17. BITZENHOFER M, Suter-Riniker F, Moor MB, Sidler D, et al
    Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease.
    PLoS One. 2022;17:e0268780.
    

    >> Share

    
    
18. DARKWA S, de Wildt G, Dalaba M, Vidzro E, et al
    "I would have to sell things in order to get the money": A qualitative exploration of willingness to pay for the RTS,S/AS01 malaria vaccine in the Volta region, Ghana.
    PLoS One. 2022;17:e0268009.
    

    >> Share

    
    
19. VILLANUEVA P, Wadia U, Crawford NW, Messina NL, et al
    The safety of co-administration of Bacille Calmette-Guerin (BCG) and influenza vaccines.
    PLoS One. 2022;17:e0268042.
    

    >> Share

    
    
20. MOSE A, Wasie A, Shitu S, Haile K, et al
    Determinants of COVID-19 vaccine acceptance in Ethiopia: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0269273.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

21. AMERICO JL, Cotter CA, Earl PL, Liu R, et al
    Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
    Proc Natl Acad Sci U S A. 2022;119:e2202069119.
    

    >> Share

    
    
22. OTIANG E, Yoder J, Manian S, Campbell ZA, et al
    Vaccination of household chickens results in a shift in young children's diet and improves child growth in rural Kenya.
    Proc Natl Acad Sci U S A. 2022;119:e2122389119.
    

    >> Share

    
    
23. NARCISO AR, Iovino F, Thorsdottir S, Mellroth P, et al
    Membrane particles evoke a serotype-independent cross-protection against pneumococcal infection that is dependent on the conserved lipoproteins MalX and PrsA.
    Proc Natl Acad Sci U S A. 2022;119:e2122386119.
    

    >> Share

    
    

    
    Science

24. KUPFERSCHMIDT K
    Monkeypox vaccination plans take shape amid questions.
    Science. 2022;376:1142-1143.
    

    >> Share

    
    

    
    Vaccine

25. TOOR J, Li X, Jit M, Trotter CL, et al
    COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00698.
    

    >> Share

    
    
26. WATANABE A, Nishida S, Burcu T, Shibahara T, et al
    Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-beta-cyclodextrin: A phase 1 clinical trial.
    Vaccine. 2022 Jun 4. pii: S0264-410X(22)00677.
    

    >> Share

    
    
27. AB RAHMAN N, Lim MT, Lee FY, Lee SC, et al
    Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00700.
    

    >> Share

    
    
28. JANSSEN DF
    A familiar species of Crank: Anti-Vaccinationists in medical history.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00665.
    

    >> Share

    
    
29. WOO EJ, Dimova RB
    Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting system.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00704.
    

    >> Share

    
    
30. BILGIN GM, Lokuge K, Glass K
    Modelling the impact of maternal pneumococcal vaccination on infant pneumococcal disease in low-income settings.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00684.
    

    >> Share

    
    
31. PATEL KM, Shafiq M, Malik AA, Cobanoglu A, et al
    Relationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00680.
    

    >> Share

    
    
32. PILLSBURY M, Carias C, Samant S, Greenberg D, et al
    Comparison of performance of varicella vaccines via infectious disease modeling.
    Vaccine. 2022 May 31. pii: S0264-410X(22)00574.
    

    >> Share

    
    
33. HISYAM BIN ISMAIL CMK, Raihan Mohammad Shabani N, Chuah C, Hassan Z, et al
    Shigella iron-binding proteins: An insight into molecular physiology, pathogenesis, and potential target vaccine development.
    Vaccine. 2022 May 31. pii: S0264-410X(22)00679.
    

    >> Share

    
    
34. MERRICK E, Weissman JP, Patel SJ
    Utilizing Google trends to monitor coronavirus vaccine interest and hesitancies.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00699.
    

    >> Share

    
    
35. SOEGIARTO G, Wulandari L, Purnomosari D, Dhia Fahmita K, et al
    Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00676.
    

    >> Share

    
    
36. EVANS B, Jombart T
    Worldwide routine immunisation coverage regressed during the first year of the COVID-19 pandemic.
    Vaccine. 2022;40:3531-3535.
    

    >> Share

    
    
37. SPARROW E, Adetifa I, Chaiyakunapruk N, Cherian T, et al
    WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
    Vaccine. 2022;40:3506-3510.
    

    >> Share

    
    
38. POLLET J, Strych U, Chen WH, Versteeg L, et al
    Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
    Vaccine. 2022;40:3655-3663.
    

    >> Share

    
    
39. OSTER G, Bornheimer R, Ottino K, Stevenson C, et al
    Adult immunization against hepatitis B: Does the number of jabs matter?
    Vaccine. 2022 May 12. pii: S0264-410X(22)00534.
    

    >> Share

    
    
40. SCHENK J, Abrams S, Litzroth A, Cornelissen L, et al
    Identifying immunity gaps for measles using Belgian serial serology data.
    Vaccine. 2022;40:3676-3683.
    

    >> Share

    
    
41. LEIGH JP, Moss SJ, White TM, Picchio CA, et al
    Factors affecting COVID-19 vaccine hesitancy among healthcare providers in 23 countries.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00545.
    

    >> Share

    
    
42. DUBE C, Paris-Robidas S, Andreani G, Gutzeit C, et al
    Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00641.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share